Joint primary and secondary care study of lithium prescribing and monitoring

Abstract

Lithium is licensed for the treatment and prophylaxis of mania, bipolar disorder, recurrent depression and intentional self-harming behaviour. Despite its effectiveness, lithium use is complicated by its narrow therapeutic range. In 2009, the National Patient Safety Agency issued a safety alert highlighting the issues and requested NHS organisations ensure reliable systems and monitoring were in place. This article explores how well the guidelines are followed in terms of lithium prescribing and monitoring across primary and secondary care.